Personalised medicine and the advantages of big data and AI-based diagnostics – Medical Device Network

Artificial intelligence (AI) and big data are transforming healthcare with high-throughput analyses of complex diseases. Machine learning and sophisticated computational methods can be used to efficiently interpret human genomes and other biomarkers, providing insights for patient treatment and with major applications in diagnostics and preventive care.

A personalised treatment plan may include preventive care for diseases that are at a higher risk of developing, for example increased screening for cancer if a patient possesses the BRCA 1 or BRCA 2 gene mutation. Additionally, AI can generate insights from genetic information, biomarkers, and other physiological data to predict how a patient will respond to different treatment options, which may help avoid adverse reactions, reduce the use of expensive or unnecessary treatments on patients that are unlikely to respond, and ultimately reduce hospitalisation and outpatient costs. For more information, GlobalDatas latest report, Precision and Personalized Medicine Thematic Research, provides insight into the most prevalent uses of personalised medicine, new applications, and the healthcare, macroeconomic, and technology themes driving growth.

Big data and bioinformatics can also offer human-centred data to be used for early drug research in lieu of, or in combination with, conventional methods like cell or animal models. This could help streamline the drug discovery process by reducing the time and money spent on inviable drug candidates, especially for conditions that translate poorly between animal models and humans. For example, laboratory mice have historically been utilised in early phase drug trials but are a poor model for genetic diversity and age-related diseases in humans. So, treatments for neurodegenerative and other age-related conditions could greatly benefit from the inclusion of human genetics in research and development (R&D).

The field of oncology has been the most accepting of personalised medicine, though other areas of medicine could greatly benefit from this medical model. Still, major barriers to commercialisation and access are funding and reimbursement. Stockholders want to invest in therapies that have a large patient pool and payers are hesitant to reimburse patients for novel diagnostic tests and treatments that lack the positive clinical data of traditional one-size-fits-all approaches. However, we could see interest in the sector resurge as increasing market competition and advances in technology rapidly drive down the cost of genetic sequencing. Physiological data is also more comprehensive and accessible than ever due to the recent growth of remote patient monitoring devices and wearable tech from the Covid-19 pandemic.

Furthermore, companies are collaborating to reduce development costs and share patient data for research. Recently, Valo Health Inc., a medical technology company, and Kahn-Sagol-Maccabi (KSM), a research and innovation center, announced they will perform joint studies utilising KSMs Tipa Biobank of more than 800,000 samples and Valos drug discovery and development platform Opal. The Tipa Biobank stores live samples, with plans to continue collecting genetic samples from the same subjects over their respective lifetimes. The collaboration provides an opportunity to utilise the growing patient data sector to capitalise on the race to get AI-designed drugs to market and could give Valo/KSM a competitive edge for developing treatments in oncology and for neurodegenerative diseases. Industry collaborations between big market players may also reassure healthcare payers that personalised technology is worth the investment, improving funding and patient identification for new trials and treatments.

Genetic and physiological data can help paint a clearer picture of overall patient health, and it is expected that the demand for preventive medicine will continue increasing as people live longer and the global elderly population grows. Looking to the future, precision and personalised medicine has the potential to expedite drug discovery, improve disease screening, and predict patient responses to treatment options, leading to improved quality of care and reduced overall healthcare costs.

Precision Micro, Small and Lead Frame / Insert Injection-Molded Plastic Components

Read this article:
Personalised medicine and the advantages of big data and AI-based diagnostics - Medical Device Network

Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit – Decibel Therapeut – Benzinga

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics DBTX, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.

A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company's website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel's pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit http://www.decibeltx.com or follow us on Twitter.

Investor Contact:Julie SeidelStern Investor Relations, Inc.julie.seidel@sternir.com212-362-1200

Media Contact:Chris RaileyTen Bridge CommunicationsChris@tenbridgecommunications.com617-834-0936

Continued here:
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit - Decibel Therapeut - Benzinga

Shutting down backup genes leads to cancer remission in mice – University of Michigan News

Abhinav Achreja, PhD, Research Fellow at the University of Michigan Biomedical Engineering and Deepak Nagrath, Ph.D. Associate Professor of Biomedical Engineering work on ovarian cancer cell research in the bio-engineering lab at the North Campus Research Center (NCRC). Image credit: Marcin Szczepanski, Michigan Engineering

The way that tumor cells enable their uncontrolled growth is also a weakness that can be harnessed to treat cancer, researchers at the University of Michigan and Indiana University have shown.

Their machine-learning algorithm can identify backup genes that only tumor cells are using so that drugs can target cancer precisely.

Most cancer drugs affect normal tissues and cells. However, our strategy allows specific targeting of cancer cells.

The team demonstrated this new precision medicine approach treating ovarian cancer in mice. Moreover, the cellular behavior that exposes these vulnerabilities is common across most forms of cancer, meaning the algorithms could provide better treatment plans for a host of malignancies.

This could revolutionize the precision medicine field because the drug targeting will only affect and kill cancer cells and spare the normal cells, said Deepak Nagrath, a U-M associate professor of biomedical engineering and senior author of the study in Nature Metabolism. Most cancer drugs affect normal tissues and cells. However, our strategy allows specific targeting of cancer cells.

This approach is known as collateral lethalityusing information gleaned from genes that cancer cells discard to find weaknesses. The human body comes with many mechanisms designed to protect against cancer. Cancer cells themselves used to contain suppressor genes that prevent their spread. Those cells however, have a clever strategy for dealing with that; they simply delete a portion of their DNAthe part that includes those suppressor genes.

In doing so, the cells typically lose other genes that are necessary for survival. To avoid death, the cells find a paraloga gene that can serve a similar function. Usually there are one or, possibly, two genes that can step in and perform the same function to keep the cell alive.

What if you could identify the right paralog and target it in a way that shuts down its vital function for the cell?

When a direct replacement for the deleted metabolic gene is not available, our algorithms use a mathematical model of the cancer cells metabolism to predict the paralogous metabolic pathway they might use, said Abhinav Achreja, a U-M research fellow in biomedical engineering and lead author on the research paper. These metabolic pathways are important to the cancer cells and can be targeted selectively.

Study abstract: Metabolic collateral lethal target identification reveals MTHFD2 paralog dependency in ovarian cancer (DOI: 10.1038/s42255-022-00636-3)

Attacking metabolic pathways essentially shuts down the cells energy source. In examining ovarian cancer cells, U-Ms team zeroed in on one gene, UQCR11, that was often deleted along with a suppressor gene. UQCR11 plays a vital role in cell respirationhow cells break down glucose for energy in order to survive.

Disturbances in this process can lead to a major imbalance of an important metabolite, NAD+, in the mitochondria, where respiration takes place. Despite all odds, ovarian cancer cells continue to thrive by relying on their backup plan.

U-Ms algorithm correctly sorted through multiple options and successfully predicted a cell missing UQCR11 would turn to the gene MTHFD2 as its backup supplier of NAD+.

Researchers at the Indiana University School of Medicine helped validate the findings in the lab. This team, led by professor of medicine Xiongbin Lu, developed genetically modified cell and animal models of ovarian cancers with the deletions. Six out of six mice tested showed complete cancer remission.

This research was supported by funding from the National Cancer Institute, Office of the Director for the National Institutes of Health, University of Michigan Precision Health Scholars Award, and Forbes Scholar Award from Forbes Institute of Cancer Discovery.

Read the original:
Shutting down backup genes leads to cancer remission in mice - University of Michigan News

Genetic Testing Before Pregnancy: What You Need To Know – Forbes

We can now screen for over 500 different types of [disorders] depending on the company or test you are using, says Dr. Keegan. This gives us the opportunity to prevent the transmission of inherited genetic disorders through the technology available and a simple blood test.

The ACOG recommends considering family history and ethnicity, in addition to the most common genetic conditions, when deciding which mutations to include. Parents may also benefit from genetic counseling, which is a service that helps people understand the results of their tests and make informed decisions throughout the process.

Here are some of the most common conditions identified through genetic carrier screening:

There are currently almost 40,000 children and adults living with cystic fibrosis in the U.S. Cystic fibrosis is a disease that affects the lungs, pancreas and other organs. People who have cystic fibrosis have difficulties breathing. The mutation involved with cystic fibrosis causes a protein to not function correctly, which then causes mucus buildup in multiple organs throughout the body.

About 1 in 7,000 males and about 1 in 11,000 females have fragile X syndrome, the most common cause of inherited intellectual disability. Fragile X is associated with lower than average IQ, developmental delays and other co-occurring health conditions including seizures, autism, hyperactivity, attention difficulties and more.

One in every 6,000 babies is born with spinal muscular atrophy, or SMA, which is a group of genetic disorders that cause a weakening of the muscles. Symptoms may vary, but people with SMA may require physical and occupational therapy, support devices such as wheelchairs or assistance with breathing. Symptoms generally worsen over time and there is no cure.

Although anyone can be a carrier, Tay-Sachs disease is more common for people of Ashkenazi Jewish ancestry, as one in every 27 members of the population is a carrier for the disease. Symptoms may include deafness, blindness, seizures, decreased muscle tone, dementia and others.

It is estimated that approximately 100,000 people in the U.S. have sickle cell disease. This inherited condition is most common in Black or African American people but can affect any race. Sickle cell disease includes a group of red blood cell disorders that can cause acute chest syndrome, anemia, blood clots or infections.

Go here to see the original:
Genetic Testing Before Pregnancy: What You Need To Know - Forbes

Verve Therapeutics to Participate in Upcoming Investor Conferences – GlobeNewswire

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences:

Live webcasts will be available in the investor section of the company's website at http://www.vervetx.com and will be archived for 60 days following the presentations.

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The companys initial two programs VERVE-101 and VERVE-201 target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off thePCSK9gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) not at goal on oral therapy. VERVE-201 is designed to permanently turn off theANGPTL3gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately in patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. For more information, please visit http://www.VerveTx.com.

Investor ContactJen RobinsonVerve Therapeutics, Inc.jrobinson@vervetx.com

Media ContactAshlea Kosikowski1ABashlea@1abmedia.com

Read the original post:
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More – BioSpace

This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.

Epigenetic Treatment Shows Potential in Spinal Cord Regeneration

Researchers reported that activation of the CBP/p300 protein family led to increased axon growth, regenerative signaling and synaptic plasticity in the spinal cord after injury in mice.

The study, led by Imperial College London,used a molecule called TTK21 to activate the genetic program to induce axon regeneration in neurons. During this process, TTK21 changes the epigenetic state by activating the CBP/p300 family of co-activator proteins, effectively leading to increased axon regeneration.

In the study, researchers began treating the mice 12 weeks after severe spinal cord injury and continued for 10 weeks. They found axon sprouting in the spinal cord and retraction of motor neurons above the injury. These changes are believed to have been spurred by increased gene expression related to regeneration, which the researchers attributed to the TTK21 treatment.

The results, while early and limited, are a step toward potential treatments for spinal cord injury.

The next steps will be to enhance the effects of the treatments and trigger the regenerated axons to connect to the rest of the nervous system. The ultimate goal is to enable animals, and eventually people, to regain movement lost from their injuries.

Neurological Consequences Evident in Long-Term COVID Study

In a recent attempt to decode the long-term impacts of COVID-19, researchers built a dataset fromthe national healthcare databases of the US Department of Veterans Affairs.

The study,led by the Clinical Epidemiology Center, Research and Development Service at VA St. Louis Health Care System,included154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls.

Results were published Thursday in Nature Medicine.

Upon examination of the data sets, the researchers noted an increased risk in a series of neurological consequences. These included: ischemic and hemorrhagic strokes, episodic disorders, extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain-Barr syndrome and encephalitis or encephalopathy.

They estimated a hazard ratio of 1.42 neurological sequelae per thousand COVID-19 cases, and 70.69 burdens per 1,000 cases.

These numbers were not impacted by the severity of the infection or the need for hospitalization. The researchers note the sample set comprised a majority of white men, so further exploration into other demographic groups may be necessary for future studies.

Novo Nordisk and Octagon Unite on Inflammatory R&D

Octagon Therapeutics, a pre-clinical biopharmaceutical focused on autoimmune disease, announced the initiation of a multi-year research collaboration with Novo Nordiskto studypotential treatments for inflammatory diseases.

Octagon will bring its functional target discovery approach and novel chemistry approach, while Novo will contribute its specific disease expertise.

Uli Stilz, vice president of the Bio-Innovation Hub at Novo Nordisk, commented on the synergies.

Combined with our disease understanding in the cardiometabolic space and Octagons approach in targeting specific lymphocyte populations that drive disease progression, it will be exciting to see what therapeutic discoveries the collaboration can lead to, he said.

Regen's RNA/DNA-Based Cancer Immunotherapy

Regen BioPharmaannounced the filing of a provisional patent application for its RNA/DNA-based approach to cancer immunotherapy.

The patent pertains to what Regen believes is the first combination of an immunotherapy and a gene silencing agent in a single drug.

The novel composition acts as a checkpoint inhibitor drug that also silences the genes that regulate T-cells and cancer cells such as NR2F6 and Survivin.

The new drug takes advantage of aptamers - a short RNA or DNA sequence that can also function as an antibody, recognizing specific proteins and binding to them. The proprietary sequence codes for inhibitory RNA, while keeping the aptamer intact on the other side. When it binds to a checkpoint such as PD-1, that RNA is converted within the cell, thus killing it.

Used to target cancer cells, this could lead to better disease control and treatment. There is also hope that this process could be used to activate T cells, improving their immunotherapeutic potential.

Toronto-Based Researchers Uncover Potential Solve for CAR T Toxicities

Allogeneic double-negative (DN) chimeric antigen receptor (CAR)-T cells inhibit tumor growth without off-tumor toxicities, a new study found.

Current CAR-T therapies approved by the FDA in treating blood cancers are limited by their level of toxicity and cost of production. Researchers from the Toronto General Hospital Research Institute, University Health Network, reported a new version of these therapies that did not have these drawbacks.

The researchers found healthy donor-derived allogeneic DNTs as a CAR-T cell therapy platform had high levels of efficacy in both the human and mouse models.

The researchers found the DN CAR-T cells were as effective as previously studied CAR-T cells but did not have the associated toxicity levels. They also come with the advantage of being made from mixed donors and remained effective even after being frozen for long periods of time. This feature could potentially overcome manufacturing challenges in the space.

The authors noted these features make DN CAR-T cellsan attractive off-the-shelf CAR-T cell therapy option.

Go here to see the original:
Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More - BioSpace

Could a pill to strengthen muscle and bone replace exercise? – Medical News Today

When we are physically active our bones and muscles work together to make them stronger. To maintain bone health, the American College of Sports Medicine recommends a combination of weight-bearing activities 35 times per week and resistance exercise 23 times a week.

Research has shown lifelong exercise to be beneficial for preserving bone health, and a reduction in physical exercise results in bone loss. The CDC advocates regular physical activity to strengthen and maintain muscle and bone, research has shown improving muscle strength can have a moderate effect in relieving joint pain for people with osteoarthritis.

Despite its benefits, modern-day living is associated with a lack of physical activity. According to the World Health Organization, physical inactivity is a serious but insufficiently addressed public health problem with up to 85% of the worlds population leading a sedentary lifestyle.

Inactivity is also associated with an increased risk of chronic disease. The British Heart Foundation attributes more than 5 million deaths worldwide to physical inactivity, which equates to one in nine deaths overall.

Chronic conditions, injury, and aging may mean it is more difficult to undertake physical activity, which can lead to muscle weakening (sarcopenia) and bone loss (osteoporosis).

New research undertaken at Tokyo Medical and Dental University (TMDU) has identified a new drug that can mimic exercise, and promote similar changes in muscle and bone.

The work, led by Professor Tomoki Nakashima, has been published in Bone Research.

In the study, the research team identified a new compound called Locamidazole (LAMZ) as a potential therapeutic drug that can cause similar effects to exercise.

To test the new compound, the researchers administered either 10mg/kg of LAMZ orally once daily, 6mg/kg LAMZ by injection twice daily, or a control solution for 14 days to male mice.

Administration of LAMZ orally and by injection showed changes in both muscle and bone. Researchers noted that the treated mice had wider muscle fibers and increased muscle strength when compared to the non-LAMZ-treated mice.

Endurance was studied using a treadmill device, the LAMZ-treated mice were less fatigued and traveled a longer distance than the non-treated mice.

In an interview with Medical News Today, Dr. Joseph Watso, assistant professor at Florida State University, who was not involved in the study, explained:

It is thought-provoking that while the changes in distance traveled by the animals were small (around 2%), the increases in adjusted maximal muscle strength and muscle fiber width were quite substantial after 14 days of LAMZ administration.

Using gene analysis, the researchers showed that LAMZ increased the number of mitochondriathe powerhouse of the cellin muscle and bone cells. They noted an increase in the expression of the gene for the PGC-1 alpha, a protein known to maintain muscle and bone cells and increase the production of mitochondria.

PCG1a is a known transcriptional coactivator that increases mitochondrial biogenesis. This is an interesting feature of the agent they identified as mitochondrial biogenesis is a hallmark physiological adaption of exercise training, Dr. Watso explained to MNT.

To understand the pathway further, the researchers orally administered LAMZ to mice whilst blocking PGC-1 alpha. They found no increase in muscle strength, indicating the effects of LAMZ on muscle and bone through PGC-1 alpha.

3D images of bone samples generated using Micro-CT showed an increase in bone thickness, density, and bone mineral content, confirming the cell study findings of increased formation and a reduction of bone loss.

We were pleased to find that LAMZ-treated mice exhibited larger muscle fiber width, greater maximal muscle strength, a higher rate of bone formation, and lower bone resorption activity, the studys lead author Takehito Ono commented.

The study has shown that LAMZ can reinforce bone and muscle with no negative effects on surrounding tissues, and can function as a therapeutic drug by reinvigorating muscle and bone via PGC- 1, mimicking physical exercise.

Dr. Watso summarized the findings:

The article provides convincing evidence in animals for an agent with a high potential to improve bone and muscle health. Like most agents evaluated in animals, the key next question is whether those findings will translate to humans. Of course, without any harmful side effects that may not have been observed in the animal studies.

He cautioned that it will be an arduous task to develop one elixir of health to replace the innumerable benefits of regular physical activity and exercise. That said, continued efforts are needed to reduce the incidence of, and burden associated with, preventable diseases.

In certain cases, medication may be the safer option than exercise, but where possible, exercise should be the first consideration for those who have the capability to be physically active, said Dr. Watso.

Despite this, it is certainly worthwhile to continue to examine population-specific risk factors and pathophysiology for potential treatment targets, he added.

View original post here:
Could a pill to strengthen muscle and bone replace exercise? - Medical News Today

Genetic Tests Create Opportunities and Confusion for BRCA Patients – Medscape

The past decade has witnessed a rapid expansion of genetic tests, including new instruments to inform patients who have been diagnosed with breast cancer about the risk of recurrence and to guide their treatment.

But the clinical significance of many of the inherited mutations that can now be identified remains unclear, and experts are torn on when and how to deploy all the new tests available. Patients are sometimes left paying out-of-pocket for exams that are not yet the standard of care, and even the most up-to-date oncologists may be uncertain how to incorporate the flood of new information into what used to be standard treatment protocols.

A quarter-century ago, Myriad Genetics introduced the first breast cancer genetic test for BRCA mutations, two genes associated with a substantially elevated risk of getting breast cancer, opening the door to a new era in genetic testing. BRCA1 and BRCA2 mutations account for as many as half of all hereditary breast cancers, and people with a problematic mutation on one of those genes have a 45% to 72% chance of developing breast cancer during their lifetimes. They may also be at higher risk for ovarian and other cancers than people without harmful BRCA mutations.

But the clinical significance is murkier for many other genetic tests.

Testing for BRCA1 and BRCA2 genes used to cost thousands of dollars. Now, for a fraction of that, doctors can order multi-gene test panels from commercial labs that look for mutations in dozens of genes. Some direct-to-consumer companies offer screening panels for a few hundred dollars, though their reliability varies.

When Jen Carbary was diagnosed with breast cancer in 2017 at age 44, genetic testing identified a mutation in a gene called PALB2 that significantly increases the risk of developing breast cancer. Guidelines suggest that breast cancer patients with a PALB2 mutation, much like those with BRCA1 and BRCA2 mutations, consider having a mastectomy to reduce the chance of a breast cancer recurrence.

"I wish genetic testing was the standard of care," said Carbary, who owed nothing for the test because her insurer covered the cost.

Carbary, who lives in Sterling Heights, Michigan, said the test results affirmed the decision she had already made to have a double mastectomy and provided important information for family members, including her 21-year-old daughter and 18-year-old son, who will likely be tested in their mid-20s or early 30s.

But some breast cancer experts are concerned that widespread testing may also identify genetic mutations whose impact is unclear, creating anxiety and leading to further testing and to treatment of questionable value that could raise costs for the health care system.

It can also confuse patients.

"It happens a lot, that patients find their way to us after getting confusing results elsewhere," said Dr. Mark Robson, chief of the breast medicine service at Memorial Sloan Kettering Cancer Center in New York City. Robson said the cancer center has a clinical genetics service, staffed by doctors and genetic counselors, that helps people make decisions about how to manage genetic testing results.

For people diagnosed with breast cancer, many professional groups, including the influential National Comprehensive Cancer Network, or NCCN, recommend limiting testing to certain people, including those with high-risk factors, such as a family history of breast cancer; those who are 45 or younger when they're diagnosed; and those with Ashkenazi Jewish ancestry.

But in 2019, the American Society of Breast Surgeons recommended a different approach: Offer genetic testing to all patients who are diagnosed with or have a personal history of breast cancer. The recommendation was controversial.

"The NCCN guidelines [cover] most of the women who needed testing, but we wanted to get them all," said Dr. Eric Manahan, a general surgeon in Dalton, Georgia, and a member of the surgeons group's board of directors.

Mutations on other genes that are associated with breast cancer are much less common than BRCA1 and BRCA2 mutations and generally don't increase the risk of developing breast cancer as much. The cancer-causing impact of these genes may be less clear than that of the BRCA genes, which have been tested for since the mid-1990s.

And the appropriate response to the less common mutations whether to consider a risk-reducing mastectomy or stepped-up screening is often unclear.

"Things get sloppier and sloppier when you look at other genes," said Dr. Steven Katz, a professor of medicine and health management and policy at the University of Michigan. "The risks tend to be lower for different cancers, and less certain and more variable. You might walk away wondering, 'Why'd I have to know that?'"

After people are diagnosed with breast cancer, genetic testing can help inform their decisions about the types of surgery to pursue for example, a high risk of recurrence or a new breast cancer might persuade some to opt for more extensive surgery, such as a double mastectomy. Testing can also provide important information to family members about their potential cancer risk.

(This type of "germline" genetic testing, as it's called, looks at mutations in the genes that people inherit from their parents. It is different from genomic tumor tests that look at specific genes or proteins in the cancer cells and can help doctors understand the rate at which the cancer cells are dividing, for example, and the likelihood of a cancer recurrence.)

Increasingly, germline genetic testing can also help guide other treatment decisions. Some patients with metastatic breast cancer who have BRCA1 or BRCA2 mutations may be good candidates for PARP inhibitors, cancer drugs that target tumors with mutations in those genes.

But genetic testing that uncovers inherited mutations in many other genes yields less clearly actionable information, even though positive results may alarm people.

At Memorial Sloan Kettering, cancer specialists focus on "therapeutic actionability," said Robson. Will testing help someone decide whether she should get a double mastectomy or provide other important guidance? "A policy of testing everyone will identify very few additional BRCA breast mutations but will cost a lot," he said.

As a result, doctors are debating how best to deploy and incorporate new genetic knowledge. Insurers are trying to figure out which to pay for.

There is both underuse of tests that science says are relevant and overuse of tests that experts say provide information that can't be interpreted with any scientific certainty.

The result may be confusion for patients newly diagnosed with breast cancer as they confront the expense of genetic tests and sometimes little guidance on the proper treatment.

Some doctors say the first step is to make sure that the small group of people who would clearly benefit are getting the genetic tests whose meaning is clearly understood. Only 15% of breast cancer patients who met select NCCN testing guidelines for inherited cancer received genetic testing, according to a 2017 study that examined data from a national household health survey between 2005 and 2015.

"I would argue that our focus needs to be on the people who are at high risk for breast cancer that aren't even identified yet," said Dr. Tuya Pal, associate director for cancer health disparities at Vanderbilt-Ingram Cancer Center and vice chair of the NCCN guidelines panel for genetic/familial high-risk assessment of breast, ovarian, and pancreatic cancers.

Patients may fall through the cracks because no one tells them they should be tested. In one analysis, 56% of high-risk breast cancer patients who didn't get genetic testing said their doctors didn't recommend it.

Even if doctors recommend genetic testing, they may lack the expertise to determine which tests people need and how to interpret the results. That's the role of genetic counselors, but their ranks are stretched thin.

The consequences can be serious. In a study of 666 breast cancer patients who received genetic testing, half of those at average risk for inherited cancer got double mastectomies based on test results that found "variants of uncertain significance," which aren't clinically actionable. As many as half of surgeons reported managing such patients the same way as those with cancer-causing mutations.

"The bulk of our research would say that there is still room for improvement in terms of clinicians getting the understanding they need," said Dr. Allison Kurian, director of the women's clinical cancer genetics program at Stanford University and a co-author of the study.

Read the rest here:
Genetic Tests Create Opportunities and Confusion for BRCA Patients - Medscape

The Future of Healthcare: Five Trends in HealthTech Services – Omnia Health Insights

GCC governments have invested significantly in healthcare infrastructure in the past couple of decades. Evidently, healthcare cities and luxurious health complexes are mushrooming, raising the quality of medical services, and aspiring to establish the gulf region as a medical hub.

With a world leading infrastructure, the healthcare sector is ready for the future that will come with a new set of foreseen and unforeseen challenges, including a growing population and density, growing life expectancy, share of population over 65, changing lifestyle, and more.

Related: Clinical Communication & Collaboration Platforms: Foundational Technology for Smart Hospitals

Conversely, the upcoming trends in health-tech services illustrate a promising perspective, empowering patients to play an active role in health management at every stage of the treatment process. Meanwhile, technology advancements will have a-far-reaching impact that enables prevention, diagnostics, treatment, rehabilitation and care.

Related: Interconnected solutions can boost personalised healthcare systems

The changing demographics and epidemiological trends are the main factors contributing to the increasing healthcare demand in the gulf countries. However, transformation programs across larger economies, such as the Kingdom of Saudi Arabia and the United Arab Emirates, are driving a fundamental change that aims to leapfrog the healthcare industry from an emerging market status to a market of opportunity and transformation.

Jad Bitar, Managing Director and Senior Partner, Boston Consulting Group (BCG)

The expanding and ageing population, high prevalence of noncommunicable diseases (NCDs), rising cost of treatment and increasing penetration of health insurance are contributing to the higher costs in the industry. Navigating through these challenges requires a deeper look into personalised healthcare, developing a patient's "digital profile. Several technologies are pushing the boundaries of traditional medicine and enabling the transition to personalised medicine and more customised treatments, including targeted and gene medicine, bionics and robotics technology, tissue engineering and 3D printing. Overall, the wave of innovation is expected to offer more personalised services and treatment options especially coupled with Artificial Intelligence (AI), Machine Learning and massive data. This will usher the era of consumer-driven digital health that has been much talked about in the last decade.

We have recently conducted extensive research across 25 cities and identified trends that are shaping the future of healthcare. With digital and technology acting as fundamental shaping forces, five key trends stand out:

Patient empowerment: Patients will take an increasingly active role in the patient journey, leveraging access to their own health records and personal health analytics, home testing kits, personal electronic monitoring devices, etc. to shape their health and become a major component in the decision-making process.

Prevention: Health systems will benefit from predictive diagnosis of diseases, supported by technologies such as AI-enabled risk profiling, epidemiological understanding of different districts and cities, and data analytics for targeted health screenings. This will be the foundation of predictive-preventive systems. 2

Personalised treatment: New technologies (e.g., tissue engineering and 3D printers) will enable personalised and more accurate treatment allowing the arrival of bespoke medicine; health systems will build and leverage a patients 'digital profile' to enable targeted treatment for individuals as well as populations with similar profiles.

Integrated delivery models: Significant shifts are underway, from in-patient to out-patient care, and the emergence of alternative patient friendly formats and seamless virtual health delivery networks, to home care and malls care, as well as other formats.

Healthcare Professional 4.0: Machine enabled diagnosis will facilitate a symbiosis between health professionals and AI, where digital image diagnostics, virtual reality, digital twins, and routine surgery will deliver greater value and better health results. 4.0 health professionals will require increased digital, cognitive and behavioral skills.

Rapid health technological advancements in the GCC result from the regions agility to overcome the COVID-19 pandemic with an expedited rollout of technology-enabled solutions. Healthcare has witnessed a more prominent and disruptive change with a massive shift towards prevention rather than cure through Health-Tech solutions that are more data-driven and are creating efficiencies in operations, costs, and delivery of care. Moving forward, decision-makers may leverage these solutions at-scale by envisaging public-private partnerships with HealthTech start-ups, consequently driving growth across the servicing chain in the health sector.

By Jad Bitar, Managing Director and Senior Partner, Boston Consulting Group (BCG)

Read the original here:
The Future of Healthcare: Five Trends in HealthTech Services - Omnia Health Insights

Argentina: Promotion of modern biotechnology and nanotechnology – Lexology

In brief

By National Law No. 27,685 ("Law"), published on 16 September 2022, Law No. 26,270 was amended, expanding throughout the entire national territory the promotion regime for the development and production of modern biotechnology and nanotechnology. The regime will be in force up to 31 December 2034.

The Law set forth the following tax benefits: (i) the accelerated amortization of the capital goods, special equipment, and parts or elements forming those new goods, which were acquired for the project; (ii) the anticipated refund for the VAT corresponding to the goods acquired for the project; and (iii) the granting of a tax credit bond equivalent to 50% of expenses paid for hiring investigative and development services from institutions that are part of the national public system of science, technology and innovation. The tax credit bond will be valid for 10 years and it will only be transferable once.

In focus

The Law includes the concept of nanotechnology in the definition of "Modern Biotechnology", which means every technological application based on rational knowledge and scientific principles that derive from biology, biochemistry, microbiology, bioinformatics, molecular biology and genetic engineering, or that uses live organisms or parts of them, either for the production of goods and services, or for the substantial improvement of products and productive processes.

The Law set forth the following tax benefits:

Click here to download the Spanish version.

Content is provided for educational and informational purposes only and is not intended and should not be construed as legal advice. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee similar outcomes. For more information, please visit:www.bakermckenzie.com/en/client-resource-disclaimer.

Link:
Argentina: Promotion of modern biotechnology and nanotechnology - Lexology

Companies In The Filters Market Are Incorporating Nanotechnology To Improve The Efficiency Of The Filters As Per The Business Research Company’s…

LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Companys research report on the filters market, nanotechnology is gaining popularity in the filters market trends. Nanotechnology in filters refers to the use of nanomaterials and nanoparticles to improve the performance of filters. One such filter system based on nanotechnology is a nanotech-based water purification system that is thought to be modular, highly efficient, and cost-effective compared to traditional water filtration procedures. These systems are made up of carbonaceous nanomaterials, metal oxide nanoparticles, zeolites, and other nanomaterials that are integrated into a polymeric matrix to improve the performance of traditional polymeric membranes. For instance, in February 2020, Parker Hannifin Corporation, a US-based motion and control technology company, and its Industrial Gas Filtration and Generation Division introduced ProTura SB Nano Pleated Filters, which is a dust collection filter used in a variety of applications. The ProTura SB Nano Pleated Filters use advanced nanofibre filtration technology whose filters are made from a 100% synthetic base media with a proprietary nanofiber layer applied to the collection surface, designed for demanding applications.

Request for a sample of the global filters market report

The global filters market size is expected to grow from $68.28 billion in 2021 to $72.23 billion in 2022 at a compound annual growth rate (CAGR) of 4.95%. The global filters market share is expected to grow to $94.30 billion in 2026 at a compound annual growth rate (CAGR) of 6.89%.

The rapidly increasing adoption of air purifiers due to increasing toxic gas release in the air causing severe health hazards is expected to fuel the filter market demand. Air toxics cause a broad range of health effects depending on the specific pollutant, the amount of exposure, and how people are exposed. People inhaling high levels of air toxics experience nose, throat and eye irritation, and breathing difficulty. Long term exposure to air toxics such as carbon monoxide, nitrogen oxides, lead and others can cause cancer and lead to a long-term damage to the respiratory, neurological, immune, and reproductive systems. For instance, according to a study from British Lung Foundation (BLF) and Asthma UK published in February 2021, nearly 6 million people aged over 65 in England are at higher risk of lung damage and asthma attacks because of toxic air. This rise in toxic air would increase the demand for air purifies thus driving the filters market growth.

Major players in the filters market are 3M Company, Airex Filter Corp, Koch Filter, Freudenberg Filtration Technologies SE & Co KG, Donaldson Company Inc, Camfil AB, Parker Hannifin Corp, DENSO Corp, Clark Air Systems, Spectrum Filtration Pvt Ltd, MANN+HUMMEL, Clear Edge Filtration Group, Pall Corporation, Danaher Corporation, TFI Filtration (India) Private Limited and Aarkays Air Equipment Private Limited.

The global filters market is segmented by product into fluid filters, ICE filters, air filters; by distribution channel into offline stores, online stores; by application into motor vehicles, consumer goods, utilities, industrial and manufacturing, others.

Asia-Pacific was the largest region in the global filters market in 2021. The regions covered in the global filters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Filters Global Market Report 2022 Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provide filters market overviews, filters market analyze and forecast market size and growth for the whole market, filters market segments and geographies, filters market trends, filters market drivers, filters market restraints, filters market leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.

The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.

Not the market you are looking for? Check out some similar market intelligence reports:

Air Purifiers Global Market Report 2022 By Technology (HEPA Filter, Activated Carbon), By Type (Dust Collectors, Fume & Smoke Collectors), By End-User (Residential, Commercial) Market Size, Trends, And Global Forecast 2022-2026

Water Purifiers Global Market Report 2022 By Technology Type (RO Water Purifier, UV Water Purifier, Gravity-Based Water Purifier), By End-User (Industrial, Commercial, Household), By Distribution Channel (Retail Stores, Direct Sales, Online), By Portability (Portable, Non-Portable), By Device Type (Wall Mounted, Countertop, Tabletop, Faucet-Mounted, Under-The-Sink (UTS)) Market Size, Trends, And Global Forecast 2022-2026

Nanotechnology Services Global Market Report 2022 - By Service (Research And Development, Information Tracking, Technology Scouting, Standardisation, Regulation Briefings), By Application (Pharmaceuticals, Medical Equipment, Food And Beverages, It), By Provider (Large Enterprise, Small And Medium Enterprise) - Market Size, Trends, And Global Forecast 2022 - 2026

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The Worlds Most Comprehensive Database

The Business Research Companys flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

See the article here:
Companies In The Filters Market Are Incorporating Nanotechnology To Improve The Efficiency Of The Filters As Per The Business Research Company's...

Insights on the Saudi Arabia Nanotechnology in Cosmetics Industry to 2028 – by Product and Nanomaterial – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Saudi Arabia Nanotechnology in Cosmetics Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering.

The country research report on Saudi Arabia nanotechnology in cosmetics market is a customer intelligence and competitive study of the Saudi Arabia market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Saudi Arabia market.

Also, factors that are driving and restraining the nanotechnology in cosmetics market are highlighted in the study. This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market. Additionally, this report provides readers with market insights and a detailed analysis of market segments to possible micro levels. The companies and dealers/distributors profiled in the report include manufacturers & suppliers of the nanotechnology in cosmetics market in Saudi Arabia.

Segments Covered

The report on Saudi Arabia nanotechnology in cosmetics market provides a detailed analysis of segments in the market based on products, and nanomaterial.

Segmentation Based on Products

Segmentation Based on Nanomaterial

Highlights of the Report

The report provides detailed insights into:

1) Demand and supply conditions of the nanotechnology in cosmetics market

2) Factor affecting the nanotechnology in cosmetics market in the short run and the long run

3) The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, and technological factors

4) Key trends and future prospects

5) Leading companies operating in the nanotechnology in cosmetics market and their competitive position in Saudi Arabia

6) The dealers/distributors profiles provide basic information of top 10 dealers & distributors operating in (Saudi Arabia) the nanotechnology in cosmetics market

7) Matrix: to position the product types

8) Market estimates up to 2028

The report answers questions such as:

1) What is the market size of the nanotechnology in cosmetics market in Saudi Arabia?

2) What are the factors that affect the growth in the nanotechnology in cosmetics market over the forecast period?

3) What is the competitive position in Saudi Arabia nanotechnology in cosmetics market?

4) What are the opportunities in Saudi Arabia nanotechnology in cosmetics market?

5) What are the modes of entering Saudi Arabia nanotechnology in cosmetics market?

Key Topics Covered:

1. Report Overview

2. Executive Summary

3. Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.2.4. Challenges

3.3. PEST-Analysis

3.4. Porter's Diamond Model for Saudi Arabia Nanotechnology in Cosmetics Market

3.5. IGR-Growth Matrix Analysis

3.6. Competitive Landscape in Saudi Arabia Nanotechnology in Cosmetics Market

4. Saudi Arabia Nanotechnology in Cosmetics Market by Products

4.1. Hair Care

4.2. Skin Care

4.3. Make-up

4.4. Sexual Well-being

4.5. Others

5. Saudi Arabia Nanotechnology in Cosmetics Market by Nanomaterial

5.1. Liposomes

5.2. Nanoemulsions

5.3. Nanocapsules

5.4. Solid Lipid Nanoparticles

5.5. Nanosilver and Nanogold

5.6. Others

6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/viwfjt

Read the original post:
Insights on the Saudi Arabia Nanotechnology in Cosmetics Industry to 2028 - by Product and Nanomaterial - ResearchAndMarkets.com - Business Wire

New technique allows researchers to scrape beyond the surface of nanomaterials – Nanowerk

Sep 23, 2022(Nanowerk News) Since the initial discovery of what has become a rapidly growing family of two-dimensional layered materials called MXenes in 2011, Drexel University researchers have made steady progress in understanding the complex chemical composition and structure, as well as the physical and electrochemical properties, of these exceptionally versatile materials. More than a decade later, advanced instruments and a new approach have allowed the team to peer within the atomic layers to better understand the connection between the materials form and function.In a paper recently published in Nature Nanotechnology ("Oxycarbide MXenes and MAX phases identification using monoatomic layer-by-layer analysis with ultralow-energy secondary-ion mass spectrometry"), researchers from Drexels College of Engineering and Polands Warsaw Institute of Technology and Institute of Microelectronics and Photonics reported a new way to look at the atoms that make up MXenes and their precursor materials, MAX phases, using a technique called secondary ion mass spectrometry.In doing so, the group discovered atoms in locations where they were not expected and imperfections in the two-dimensional materials that could explain some of their unique physical properties. They also demonstrated the existence of an entirely new subfamily of MXenes, called oxycarbides, which are two-dimensional materials where up to 30% of carbon atoms are replaced by oxygen.A new technique using secondary-ion mass spectrometry has given Drexel researchers a fresh look at the two-dimensional materials they have been studying for more than a decade. (Image: Drexel University)This discovery will enable researchers to build new MXenes and other nanomaterials with tunable properties best suited for specific applications from antennas for 5G and 6G wireless communication and shields for electromagnetic interference; to filters for hydrogen production, storage and separation; to wearable kidneys for dialysis patients.Better understanding of the detailed structure and composition of two-dimensional materials will allow us to unlock their full potential, said Yury Gogotsi, PhD, Distinguished University and Bach professor in the College, who led the MXene characterization research. We now have a clearer picture of why MXenes behave the way they do and will be able to tailor their structure and therefore behaviors for important new applications.Secondary-ion mass spectrometry (SIMS) is a commonly used technique to study solid surfaces and thin films and how their chemistry changes with depth. It works by shooting a beam of charged particles at a sample, which bombards the atoms on the surface of the material and ejects them a process called sputtering. The ejected ions are detected, collected and identified based on their mass and serve as indicators of the composition of the material.While SIMS has been used to study multi-layered materials over the years, the depth resolution has been limited examining the surface of a material (several angstroms). A team led by Pawel Michalowski, PhD, from Polands Institute of Microelectronics and Photonics, made a number of improvements to the technique, including adjusting the angle and energy of the beam, how the ejected ions are measured; and cleaning the surface of the samples, which allowed them to sputter samples layer by layer. This allowed the researchers to view the sample with an atom-level resolution that had not been previously possible.The closest technique for analysis of thin layers and surfaces of MXenes is X-ray photoelectron spectroscopy, which we have been using at Drexel starting from the discovery of the first MXene, said Mark Anayee, a doctoral candidate in Gogotsis group. While XPS only gave us a look at the surface of the materials, SIMS lets us analyze the layers beneath the surface. It allows us to remove precisely one layer of atoms at a time without disturbing the ones beneath it. This can give us a much clearer picture that would not be possible with any other laboratory technique.As the team peeled back the upper layer of atoms, like an archaeologist carefully unearthing a new find, the researchers began to see the subtle features of the chemical scaffolding within the layers of materials, revealing the unexpected presence and positioning of atoms, and various defects and imperfections.We demonstrated the formation of oxygen-containing MXenes, so-called oxycarbides. This represents a new subfamily of MXenes which is a big discovery! said Gogotsi. Our results suggest that for every carbide MXene, there is an oxycarbide MXene, where oxygen replaces some carbon atoms in the lattice structure.Since MAX and MXenes represent a large family of materials, the researchers further explored more complex systems that include multiple metal elements. They made several pathbreaking observations, including the intermixing of atoms in chromium-titanium carbide MXene which were previously thought to be separated into distinct layers. And they confirmed previous findings, such as the complete separation of molybdenum atoms to outer layers and titanium atoms to the inner layer in molybdenum-titanium carbide.All of these findings are important for developing MXenes with a finely tuned structure and improved properties, according to Gogotsi.We can now control not only the total elemental composition of MXenes, but also know in which atomic layers the specific elements like carbon, oxygen, or metals are located, said Gogotsi. We know that eliminating oxygen helps to increase the environmental stability of titanium carbide MXene and increase its electronic conductivity. Now that we have a better understanding of how much additional oxygen is in the materials, we can adjust the recipe so to speak to produce MXenes that do not have it, and as a result more stable in the environment.The team also plans to explore ways to separate layers of chromium and titanium, which will help it develop MXenes with attractive magnetic properties. And now that the SIMS technique has proven to be effective, Gogotsi plans to use it in future research, including his recent $3 million U.S. Department of Energy-funded effort to explore MXenes for hydrogen storage an important step toward the development of a new sustainable energy source.In many ways, studying MXenes for the last decade has been mapping uncharted territory, said Gogotsi. With this new approach, we have better guidance on where to look for new materials and applications.

View original post here:
New technique allows researchers to scrape beyond the surface of nanomaterials - Nanowerk

Atomic-scale imaging reveals a facile route to crystal formation – Nanowerk

Sep 23, 2022(Nanowerk News) What do clouds, televisions, pharmaceuticals, and even the dirt under our feet have in common? They all have or use crystals in some way. Crystals are more than just fancy gemstones. Clouds form when water vapor condenses into ice crystals in the atmosphere. Liquid crystal displays are used in a variety of electronics, from televisions to instrument panels. Crystallization is an important step for drug discovery and purification. Crystals also make up rocks and other minerals. Their crucial role in the environment is a focus of materials science and health sciences research.Scientists have yet to fully understand how crystallization occurs, but the importance of surfaces in promoting the process has long been recognized. Research from Pacific Northwest National Laboratory (PNNL), the University of Washington (UW), and Durham University sheds new light on how crystals form at surfaces.Their results were published in Science Advances ("Hydroxide films on mica form charge-stabilized microphases that circumvent nucleation barriers").Aluminum hydroxide, depicted here in orange, undergoes fluctuations between structures before forming an ordered crystal. (Illustration by Nathan Johnson, Pacific Northwest National Laboratory)Previous studies on crystallization led scientists to form the classical nucleation theorythe predominant explanation for why crystals begin to form, or nucleate. When crystals nucleate, they begin as very small ephemeral clusters of just a few atoms. Their small size makes the clusters extremely difficult to detect. Scientists have managed to collect only a few images of such processes.New technologies are making it possible to visualize the crystallization process as never before, said PNNL Physical Sciences Division Chemist Ben Legg. He partnered with PNNL Battelle Fellow and UW Affiliate Professor James De Yoreo to do just that. With the help of Professor Kislon Voitchovsky from Durham University in England, they used a technique called atomic force microscopy to watch the nucleation of an aluminum hydroxide mineral on a mica surface in water.Mica is a common mineral, found in everything from drywall to cosmetics. It often provides a surface for other minerals to nucleate and grow. For this study, however, its most important feature was its extremely flat surface, which allowed researchers to detect the few-atom clusters as they formed on the mica.What Legg and De Yoreo observed was a crystallization pattern that was not expected from the classical theory. Instead of a rare event in which a cluster of atoms reaches a critical size and then grows across the surface, they saw thousands of fluctuating clusters that coalesced into an unexpected pattern with gaps that persisted between crystalline "islands."After careful analysis of the results, the researchers concluded that while certain aspects of the current theory held true, ultimately their system followed a nonclassical pathway. They attribute this to electrostatic forces from charges on the mica surface. Because many types of materials form charged surfaces in water, the researchers hypothesize that they observed a widespread phenomenon and are excited to look for other systems where this nonclassical process might occur.Assumptions from classical nucleation theory have far-reaching implications in disciplines ranging from materials science to climate prediction, said De Yoreo. The results from our experiments can help produce more accurate simulations of such systems.

The rest is here:
Atomic-scale imaging reveals a facile route to crystal formation - Nanowerk

Northwestern announces new global primary care center to foster health care equity in the developing world – Northwestern Now

Northwestern University has announced a major new center focused on improving the quality of primary care to improve primary care services and systems throughout the world.

A gift from the Patrick G. 59, 09 H (97, 00 P) and Shirley W. Ryan 61, 19 H (97, 00 P) Family will endow the Ryan Family Center for Global Primary Care within Northwestern University Feinberg School of Medicines Robert J. Havey, MD Institute for Global Health, whose mission is to improve health for a better world.

The primary care centers focus within that aim is to collaborate with partner institutions in international environments where critical health care is most needed. Northwestern will help identify opportunities for research and training, build capacity for more primary care patients and, ultimately, improve health promotion, disease prevention, treatment, rehabilitation and palliative care. The gift is part of a transformational $480 million gift from the Ryan Family to the University that was announced in September 2021.

This wonderful gift from the Ryan Family enables Northwestern to expand our critically important work across the globe to improve lives and transform human health, said Dr. Eric G. Neilson, Lewis Landsberg Dean and Vice President for Medical Affairs at Feinberg. It is support like this that accelerates the pace of discovery for some of societys most important health issues. We are very grateful for their commitment to the science in medicine.

With the centers support, Feinberg faculty will conduct research and support scientific laboratories in these collaborating institutions, and Feinberg students and trainees will travel globally for pilot projects in primary care research.

With this visionary gift, the Ryans are putting Northwesterns faculty in a position to help reinvent primary care on a global scale, Northwestern President Michael H. Schill said. This represents one of our most urgent directives as an institution, one with as far-reaching effects as anything undertaken at a university like ours.

Dr. Robert J. Havey 80 MD, 83 GME, 84 GME (08, 13 P), deputy director of the Havey Institute for Global Health,said the goal of the Institute for Global Health is to find sustainable solutions to improve the health and health care of populations in under-resourced countries around the world. He noted that primary care is the foundation needed for health care to be affordable and effective.

The new Ryan Family Center for Global Primary Care will allow the Institute to find more efficient ways to improve and expand primary care systems to serve the billions of people around the world who currently have poor access to quality health care, said Havey, also a clinical professor ofmedicinein the division ofgeneral internal medicine and geriatrics, and a long-time general internist with Northwestern Medical Group. This is a humanitarian, economic and social stability crisis, occurring at a time of unprecedented global population growth. All of us at the Institute are grateful to the Ryan Family for recognizing and helping support this critical need.

As the largest donors in Northwesterns history, the Ryan Family has made broad and deep philanthropic investments across the institution, includingacademics. The Ryans have given in support of hundreds of different University programs. Among the most notable are:

Patrick G. Ryan is a 1959 Northwestern graduate. He received his undergraduate degree in business from what was then called the School of Business and now is named the Kellogg School of Management. He also received an honorary degree from the University in 2009 in appreciation for his 14 years of service as chairman of Northwesterns Board of Trustees. In 2013, he was inducted into Northwesterns Athletics Hall of Fame.

Shirley Welsh Ryan is a 1961 Northwestern graduate. She received her undergraduate degree in English Literature from what was then called the College of Arts and Sciences and is now named the Weinberg College of Arts and Sciences. In 2019, Northwestern awarded Mrs. Ryan the honorary title of Doctor of Humane Letters.

Mr. Ryan is distinguished as one of Chicagos most successful entrepreneurs and prominent civic leaders. His first business venture while a student involved selling scrapbooks to fellow students, which paid for his Northwestern education. Mr. Ryan founded and served for 41 years as CEO of Aon Corporation, the leading global provider of risk management, insurance and reinsurance brokerage. At the time of his retirement, Aon had nearly $8 billion in annual revenue with more than 500 offices in 120 countries.

In 2010, Mr. Ryan founded Ryan Specialty, a service provider of specialty products and solutions for insurance brokers, agents and carriers. The firm provides distribution, underwriting, product development, administration and risk management services by acting as a wholesale broker and a managing underwriter.

Mr. Ryan currently serves as chairman and CEO of Ryan Specialty Holdings, Inc., which completed its initial public offering in July 2021. The firms shares trade on the New York Stock Exchange under the symbol RYAN. Mr. Ryan is distinct in having founded and built two major New York Stock Exchange traded insurance companies.

Mr. Ryan is a member of the Chicago Business Hall of Fame, and a member and past president of the Economic Club of Chicago. He also is a member of the International Insurance Hall of Fame and the Automotive Hall of Fame, a member and past chairman of Northwesterns Board of Trustees, a recipient of the esteemed Horatio Alger Award and a member of the American Academy of Arts and Sciences.

Shirley Welsh Ryan is founder of Pathways.org, which is used by 40 million parents and healthcare professionals annually through its video-based website and social media in every country except North Korea. Three hundred U.S. institutions of higher learning use Pathway.orgs free materials. Mrs. Ryans pioneering work to empower every infants fullest physical development has won numerous awards. Two U.S. presidents have appointed her to the National Council on Disability in Washington, D.C., which advises the U.S. Congress on disability policy.

In 2017, Pathways.org merged with the Shirley Ryan AbilityLab, acclaimed for 32 years as the number one U.S. rehabilitation hospital by U.S. News & World Report.

The Pathways.org Medical Round Table (P.M.R.T.), created in 1990, is the first Infant Milestone Chart of typical and atypical development to be endorsed by the American Academy of Pediatrics (A.A.P.). All Pathways.org material is in accord with the leadership of P.M.R.T. and A.A.P.

Mrs. Ryan is a strong believer in the power of early infant detection, therapeutic intervention, universal accessibility, and the concept that all children can learn. She serves on the boards of University of Notre Dame, the Lyric Opera of Chicago, the Art Institute of Chicago, the Chicago Council on Global Affairs, Alain Locke Charter School and WTTW-PBS. She also has served on the boards of the Kennedy Center for Performing Arts in Washington, D.C., and Ronald McDonald House Charities; has chaired the Chicago Community Trust; and founded the Lincoln Park Zoo Womens Board. For 46 years, Mrs. Ryan has led a Northwestern graduate-level course entitled Learning for Life.

Mrs. Ryan has been awarded honorary doctorates from Northwestern, the University of Notre Dame and the University of Illinois at Chicago. She also has received the Chicago History Museum Award for Distinction in Civic Leadership.

In addition to earning her B.A. from Northwestern, Mrs. Ryan studied at the Sorbonne of the University of Paris and the Ecoledu Louvre in Paris.

In addition to Mr. and Mrs. Ryan, the Ryan Family includes Pat 97 JD, MBA and Lydia; Rob 00 JD, MBA and Jennifer; and Corbett.

This is one in a series of announcements being made this fall related to the Ryan Familys $480 million gift to Northwestern, which wasannounced in September 2021.

Originally posted here:
Northwestern announces new global primary care center to foster health care equity in the developing world - Northwestern Now

Cell Rover: Exploring and augmenting the inner world of the cell – Nanowerk

Sep 22, 2022(Nanowerk News) Researchers at the MIT Media Lab have designed a miniature antenna that can operate wirelessly inside of a living cell, opening up possibilities in medical diagnostics and treatment and other scientific processes because of the antennas potential for monitoring and even directing cellular activity in real-time.The most exciting aspect of this research is we are able to create cyborgs at a cellular scale, says Deblina Sarkar, assistant professor and AT&T Career Development Chair at the MIT Media Lab and head of the Nano-Cybernetic Biotrek Lab. We are able to fuse the versatility of information technology at the level of cells, the building blocks of biology.A paper describing the research was published in the journal Nature Communications ("Cell Rovera miniaturized magnetostrictive antenna for wireless operation inside living cells").An artist's rendition of the Cell Rover, an intracellular antenna for exploring and augmenting the inner world of the cell. (Image: Irakli Zurabishvili for Deblina Sarkar, with models by IronWeber and Lauri Purhonen)The technology, named Cell Rover by the researchers, represents the first demonstration of an antenna that can operate inside a cell and is compatible with 3D biological systems. Typical bioelectronic interfaces, Sarkar says, are millimeters or even centimeters in size, and are not only highly invasive but also fail to provide the resolution needed to interact with single cells wirelessly especially considering that changes to even one cell can affect a whole organism.The antenna developed by Sarkars team is much smaller than a cell. In fact, in the teams research with oocyte cells, the antenna represented less than .05 percent of the cell volume, putting it well below a size that would intrude upon and damage the cell.Finding a way to build an antenna of that size to work inside a cell was a key challenge.This is because conventional antennas need to be comparable in size to the wavelength of the electromagnetic waves they transmit and receive. Such wavelengths are very large they represent the velocity of light divided by the wave frequency. At the same time, increasing the frequency in order to reduce that ratio and the size of the antenna is counterproductive because high frequencies produce heat damaging to living tissue.The antenna developed by the Media Lab researchers converts electromagnetic waves into acoustic waves, whose wavelengths are five orders of magnitude smaller representing the velocity of sound divided by the wave frequency than those of the electromagnetic waves.This conversion from electromagnetic to acoustic waves is accomplished by fabricating the miniature antennas using material that is referred to as magnetostrictive. When a magnetic field is applied to the antenna, powering and activating it, magnetic domains within the magnetostrictive material align to the field, creating strain in the material, the way metal bits woven into a piece of cloth could react to a strong magnet, causing the cloth to contort.When an alternating magnetic field is applied to the antenna, the varying strain and stress (pressure) produced in the material is what creates the acoustic waves in the antenna, says Baju Joy, a student in Sarkar's lab and the lead author of this work. "We have also developed a novel strategy using a non-uniform magnetic field to introduce the rovers into the cells," Joy adds.Configured in this way, the antenna could be used to explore the fundamentals of biology as natural processes occur, Sarkar says. Instead of destroying cells to examine their cytoplasm as is typically done, the Cell Rover could monitor the development or division of a cell, detecting different chemicals and biomolecules such as enzymes, or physical changes such as in cell pressure all in real-time and in vivo.Materials such as polymers that undergo change in mass or stress in response to chemical or biomolecular changes already used in medical and other research could be integrated with the operation of the Cell Rover, according to the researchers. Such an integration could provide insights not afforded by the current observational techniques that involve destruction of the cell.With such capabilities, the Cell Rovers could be valuable in cancer and neurodegenerative disease research, for example. As Sarkar explains, the technology could be used to detect and monitor biochemical and electrical changes associated with the disease over its progression in individual cells. Applied in the field of drug discovery, the technology could illuminate the reactions of live cells to different drugs.Because of the sophistication and scale of nanoelectronic devices such as transistors and switches representing five decades of tremendous advancements in the field of information technology, Sarkar says the Cell Rover, with its mini antenna, could carry out functions ranging all the way to intracellular computing and information processing for autonomous exploration and modulation of the cell. The research demonstrated that multiple Cell Rovers can be engaged, even within a single cell, to communicate among themselves and outside of the cells.The Cell Rover is an innovative concept as it can embed sensing, communication and information technology inside a living cell, says Anantha P. Chandrakasan, dean of the MIT School of Engineering and the Vannevar Bush Professor of Electrical Engineering and Computer Science. This opens up unprecedented opportunities for extremely precise diagnostics, therapeutics, and drug discovery, as well as creating a new direction at intersection between biology and electronic devices.The researchers named their intracellular antenna technology Cell Rover to invoke, like that of a Mars rover, its mission to explore a new frontier.You can think of the Cell Rover, says Sarkar, as being on an expedition, exploring the inner world of the cell.

Excerpt from:
Cell Rover: Exploring and augmenting the inner world of the cell - Nanowerk

Wrapping of nanosize copper cubes can help convert carbon dioxide into other chemicals – Nanowerk

Sep 22, 2022(Nanowerk News) As the need to mitigate climate change accelerates, scientists are trying to find new ways to reduce carbon dioxide emissions. One process, called electrochemical reduction or electrolysis, uses electricity and a catalyst to convert carbon dioxide into organic products that can be used in other ways. Unlike conversion between water and hydrogen, chemical recycling of carbon dioxide can produce various useable products because carbon can develop vast varieties of organic structures.One way to achieve electrochemical reduction of carbon dioxide uses very tiny pieces of copper. While bulk copper metal has known to convert carbon dioxide into various organic molecules, these small pieces of copper can further improve catalytic activity not only by the increase of its surface area but also by the unique electronic structure of copper emerged from nanosizing.The organic layer grown on cuprous oxide nanocube improved CO2 reduction selectivity of Cu species wrapped by it, and also maintained its cubic structure during catalysis. (Image: Shoko Kume, Hiroshima University)In a paper published in Chemical Communications ("Uniform wrapping of copper(i) oxide nanocubes by self-controlled copper-catalyzed azidealkyne cycloaddition toward selective carbon dioxide electrocatalysis"), researchers explain a process for improving the way the copper nanocubes convert carbon dioxide, by improving their selectivity. Selectivity refers to the ability of a catalyst to produce a desired product over unwanted byproducts.Recent developments in carbon dioxide reduction using copper electrocatalysts can convert the gas into hydrocarbons and alcohol, but the selectivity of various copper-related electrocatalysts developed so far is still elusive, because they tend to lose activity through structural reorganization during the catalysis, said Shoko Kume, associate professor at the Graduate School of Advanced Science and Engineering at Hiroshima University in Japan.Researchers discovered that this problem can be solved by growing an organic layer on top of the nanocubes. First, a pair of monomers were added to the copper oxide nanocube. These monomers were tethered by the chemistry on copper oxide and an even organic layer grew on the surface of the cubes. This new organic layer helps improve carbon dioxide reduction selectivity, in part because carbon dioxide has poor solubility and the organic layer the researchers produced has hydrophobic properties, meaning it repels excessive water, from which unwanted hydrogen is produced.The wrapping improved carbon dioxide reduction of the copper beneath this organic layer by suppressing hydrogen evolution, and also maintained the cubic structure throughout the catalyst operation, said Kume.Another important factor for improving the quality of the organic layer was the temperature at the time of the growth, with the best results found at room temperature. Under the best conditions, the layer is flat with a thickness of several molecules. Even the thin layer readily permeates carbon dioxide and allows the wrapped copper to undergo electroreduction, protecting the metals and helping the cubes retain their shape.Currently, copper nanocubes are not widely adopted as a method for carbon dioxide reduction because they are unstable and do not have the level of selectivity needed to effectively recycle the carbon dioxide into other chemical products. The findings of this paper highlight a new method of creating an electrocatalyst using copper nanocubes that can solve some of these problems. Researchers also point out, looking ahead, that the method can be modified to control both the selectivity and improve how the catalysts work.Our current method can introduce a vast variety of organic structures within the layer, which can be involved in the carbon dioxide reduction process to control its selectivity and efficiency, said Kume. It can also be used to control the dynamic behavior of metal species during catalysis, which can develop catalysts with long life and a tolerance for impurities.

More:
Wrapping of nanosize copper cubes can help convert carbon dioxide into other chemicals - Nanowerk

NGA Puts Machine Learning to Work to Speed Mission, Further Research – HS Today – HSToday

The National Geospatial-Intelligence Agency is well known for analysis of imagery and maps, but text, or written language, is a key part of the process. In a year-long study, members of the NGA workforce reported that text reading and generation occupy up to 80% of their average workflow, whether in conducting research, reviewing documents, tipping imagery or generating reports.

NGA conducted the study of natural language processing through a federally funded research and development center, with hopes to significantly raise awareness of the potential time savings and intelligence gains made possible through greater access to text analytics software.

If a picture is worth a thousand words, NGA is in the business of countless words, says Monica Lipscomb of NGA Research, who serves as the NLP program manager. Map reading, legend generation, and image notation are obvious examples.

Natural language processing, also known as human language technology, enables the automated sifting, sorting, translating, comprehending and sensemaking of billions of words.In addition to speeding the analytic workflow, NLP has applicability to workflows involving security, finance, policy, records management and safety of navigation alerts, according to Lipscomb. The Source Maritime Automated Processing System, launched in early 2022, is driven by natural language processing and basic machine learning. SMAPS has reportedly cut in half the time needed to process incoming incident messages and generate alerts.

Lipscomb says the agency wants to facilitate mission advancement in other NGA workflows akin to those achieved through SMAPS.

Many NGA employees know that NLP resources are available, but they have difficulty knowing where to find them or how to orient them towards NGA topics of interest, she said.

As a next step, NGA will discuss natural language processing resources available throughout the Intelligence Community and generate an enterprise-wide community of interest.

Read more at NGA

See original here:
NGA Puts Machine Learning to Work to Speed Mission, Further Research - HS Today - HSToday

Machine learning has predicted the winners of the Worlds – CyclingTips

The singularity is coming for us, day by creeping day. Artificial intelligence is starting to write about cycling. It is starting to create pictures of cycling. And now, it is starting to predict the results of races that havent even happened yet.

There are humans involved at some point there always are, before the end of everything. In this case, it is a data and analytics consultancy called Decision Inc., Australia. The humans developed the modelling, fed it to their machine learning tool, let it marinate for a bit [that may be creative license] and then, the magic happened.

Machine Learning is a form of Artificial Intelligence which uses advanced data analytics [to] solve complex issues, explained Decision Inc, Australia CEO, Aiden Heke. It uses algorithms to best imitate how humans solve problems or predict outcomes.

Since the technology has evolved so much over the past few decades, we thought: why not use it to predict the outcome of the UCI World Championships?

First up, the womens road race:

A caveatthe Machines were crunching their numbers before Annemiek van Vleuten crashed out of the mixed team time trial, putting her start at risk. Also, apparently The Machines dont rate Grace Brown as a top 10 favourite. But all that aside? Those are certainly some credible names.

To the men:

Again, some curiosities in here for me. The podium seems credible, but I think Van der Poel is a bit more of a dark horse than this is letting on. Pogaar seems low; Almeida seems high. Im also furious about the Juraj Sagan erasure, but that is a me thing, not a you thing, and certainly not an AI thing.

Decision Inc. is likening their cycling foray to Deep Blue, an early machine learning venture from the mid-1990s that famously vanquished chess grandmaster Garry Kasparov. Its why were putting it to the test, to see just how far its come, said Decision Inc. CEO Aiden Heke. Were keen for everyone who fancies themselves as a bit of an expert on cycling to see if they can win where Kasparov couldnt: against the Machine.

If you want to show that you know more about this weekends cycling than a series of computer calculations, you can head to the companys Instagram account where you could win some signed cycling goodies.

Or, you can just wade into the comments here and tell us who your pick is. Thatd be fun too.

See original here:
Machine learning has predicted the winners of the Worlds - CyclingTips

Machine Learning Can Be Used to Improve the Ability to Predict Adverse Pregnancy Outcomes in Women with Lupus – Lupus Foundation of America

Nearly 20% of pregnancies in people with lupus result in an adverse pregnancy outcome (APO). In a new study, scientists were able to improve prediction accuracy of APOs using machine learning. Machine learning refers to the process by which a computer is able to improve its own performance by continuously incorporating new data into an existing statistical model.

Using a previously developed APO prediction model utilizing data from a larger multi-center, multi-ethnic study of lupus pregnancies known as the Predictors of pRegnancy Outcome: bioMarkers In Antiphospholid Antibody Syndrome and the Systemic Lupus Erythematosus (PROMISSE) study, and statistical analysis coupled with machine learning, researchers analyzed data from 385 women in their first trimester of pregnancy. They identified lupus anticoagulant positivity, disease assessment score, diastolic blood pressure or resting heartbeat, current use of antihypertension medication, and platelet count as significant baseline predictors of APO.

Researchers suggest that the ability to identify, lupus patients at high risk of APO early in pregnancy, could enhance the capacity to manage these patients and conduct trials of new treatments to prevent pre-eclampsia and placental insufficiency.

Further studies to identify new biomarkers and risk factors for APO are still needed. The Lupus Foundation of America provided the study author, Jane Salmon, MD, with a three-year grant for her IMPACT study, the first trial of a biologic therapy to prevent adverse pregnancy outcomes in high-risk pregnancies in patients with antiphospholipid syndrome (APS) with or without systemic lupus erythematosus (SLE), which also helped support this new research. Learn more about lupus and pregnancy.

Read the study

Read the original post:
Machine Learning Can Be Used to Improve the Ability to Predict Adverse Pregnancy Outcomes in Women with Lupus - Lupus Foundation of America